Standardized mortality rate increased for those receiving monotherapy, those receiving four or more meds, those without comorbidities
Rates of depressive and anxiety symptoms increased during pregnancy and postpartum for women with epilepsy
Risks for ASD, intellectual disability may be increased with prenatal exposure to topiramate, valproate, certain duotherapies
Current evidence does not support increased suicidality for certain newer antiseizure medications; class warning may not be merited
No significant differences in language development seen at age 2 years for children born to mothers with epilepsy